Literature DB >> 35606145

Calpain-2 Mediates MBNL2 Degradation and a Developmental RNA Processing Program in Neurodegeneration.

Lee-Hsin Wang1,2, Chien-Yu Lin2, Yu-Mei Lin2, Luc Buée3, Nicolas Sergeant3, David Blum3, Yijuang Chern1,2,4, Guey-Shin Wang5,2,4.   

Abstract

Increasing loss of structure and function of neurons and decline in cognitive function is commonly seen during the progression of neurologic diseases, although the causes and initial symptoms of individual diseases are distinct. This observation suggests a convergence of common degenerative features. In myotonic dystrophy type 1 (DM1), the expression of expanded CUG RNA induces neurotransmission dysfunction before axon and dendrite degeneration and reduced MBNL2 expression associated with aberrant alternative splicing. The role of loss of function of MBNL2 in the pathogenesis of neurodegeneration and the causal mechanism of neurodegeneration-reduced expression of MBNL2 remain elusive. Here, we show that increased MBNL2 expression is associated with neuronal maturation and required for neuronal morphogenesis and the fetal to adult developmental transition of RNA processing. Neurodegenerative conditions including NMDA receptor (NMDAR)-mediated excitotoxicity and dysregulated calcium homeostasis triggered nuclear translocation of calpain-2, thus resulting in MBNL2 degradation and reversal of MBNL2-regulated RNA processing to developmental patterns. Nuclear expression of calpain-2 resembled its developmental pattern and was associated with MBNL2 degradation. Knock-down of calpain-2 expression or inhibition of calpain-2 nuclear translocation prevented neurodegeneration-reduced MBNL2 expression and dysregulated RNA processing. Increased calpain-2 nuclear translocation associated with reduced MBNL2 expression and aberrant RNA processing occurred in models for DM1 and Alzheimer's disease (AD) including EpA960/CaMKII-Cre mice of either sex and female APP/PS1 and THY-Tau22 mice. Our results identify a regulatory mechanism for MBNL2 downregulation and suggest that calpain-2-mediated MBNL2 degradation accompanied by re-induction of a developmental RNA processing program may be a converging pathway to neurodegeneration.SIGNIFICANCE STATEMENT Neurologic diseases share many features during disease progression, such as cognitive decline and brain atrophy, which suggests a common pathway for developing degenerative features. Here, we show that the neurodegenerative conditions glutamate-induced excitotoxicity and dysregulated calcium homeostasis induced translocation of the cysteine protease calpain-2 into the nucleus, resulting in MBNL2 degradation and reversal of MBNL2-regulated RNA processing to an embryonic pattern. Knock-down or inhibition of nuclear translocation of calpain-2 prevented MBNL2 degradation and maintained MBNL2-regulated RNA processing in the adult pattern. Models of myotonic dystrophy and Alzheimer's disease (AD) also showed calpain-2-mediated MBNL2 degradation and a developmental RNA processing program. Our studies suggest MBNL2 function disrupted by calpain-2 as a common pathway, thus providing an alternative therapeutic strategy for neurodegeneration.
Copyright © 2022 the authors.

Entities:  

Keywords:  Alzheimer's disease; MBNL2; RNA-processing; calpain-2; excitotoxicity; myotonic dystrophy

Mesh:

Substances:

Year:  2022        PMID: 35606145      PMCID: PMC9233439          DOI: 10.1523/JNEUROSCI.2006-21.2022

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.709


  41 in total

1.  Alzheimer's disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits.

Authors:  Katharina Schindowski; Alexis Bretteville; Karelle Leroy; Séverine Bégard; Jean-Pierre Brion; Malika Hamdane; Luc Buée
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 2.  Proteasome inhibitors: valuable new tools for cell biologists.

Authors:  D H Lee; A L Goldberg
Journal:  Trends Cell Biol       Date:  1998-10       Impact factor: 20.808

Review 3.  Calpain research for drug discovery: challenges and potential.

Authors:  Yasuko Ono; Takaomi C Saido; Hiroyuki Sorimachi
Journal:  Nat Rev Drug Discov       Date:  2016-11-11       Impact factor: 84.694

Review 4.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

Review 5.  Glutamate receptors, neurotoxicity and neurodegeneration.

Authors:  Anthony Lau; Michael Tymianski
Journal:  Pflugers Arch       Date:  2010-03-14       Impact factor: 3.657

6.  Calcium signaling and neurodegenerative diseases.

Authors:  Ilya Bezprozvanny
Journal:  Trends Mol Med       Date:  2009-02-21       Impact factor: 11.951

7.  MBNL Sequestration by Toxic RNAs and RNA Misprocessing in the Myotonic Dystrophy Brain.

Authors:  Marianne Goodwin; Apoorva Mohan; Ranjan Batra; Kuang-Yung Lee; Konstantinos Charizanis; Francisco José Fernández Gómez; Sabiha Eddarkaoui; Nicolas Sergeant; Luc Buée; Takashi Kimura; H Brent Clark; Joline Dalton; Kenji Takamura; Sebastien M Weyn-Vanhentenryck; Chaolin Zhang; Tammy Reid; Laura P W Ranum; John W Day; Maurice S Swanson
Journal:  Cell Rep       Date:  2015-08-06       Impact factor: 9.423

8.  Ivermectin is a specific inhibitor of importin α/β-mediated nuclear import able to inhibit replication of HIV-1 and dengue virus.

Authors:  Kylie M Wagstaff; Haran Sivakumaran; Steven M Heaton; David Harrich; David A Jans
Journal:  Biochem J       Date:  2012-05-01       Impact factor: 3.857

9.  Alternative splicing rewires Hippo signaling pathway in hepatocytes to promote liver regeneration.

Authors:  Sushant Bangru; Waqar Arif; Joseph Seimetz; Amruta Bhate; Jackie Chen; Edrees H Rashan; Russ P Carstens; Sayeepriyadarshini Anakk; Auinash Kalsotra
Journal:  Nat Struct Mol Biol       Date:  2018-09-24       Impact factor: 15.369

10.  Transcriptional signatures of synaptic vesicle genes define myotonic dystrophy type I neurodegeneration.

Authors:  Antonio Jimenez-Marin; Ibai Diez; Garazi Labayru; Andone Sistiaga; Maria C Caballero; Pol Andres-Benito; Jorge Sepulcre; Isidro Ferrer; Adolfo Lopez de Munain; Jesus M Cortes
Journal:  Neuropathol Appl Neurobiol       Date:  2021-05-17       Impact factor: 6.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.